

UCLA

UCLA Previously Published Works

Title

Augmented Th17-stimulating activity of BMDCs as a result of reciprocal interaction between $\gamma\delta$ and dendritic cells

Permalink

<https://escholarship.org/uc/item/6599d6c9>

Authors

Sun, Deming
Ko, Minhee K
Shao, Hui
et al.

Publication Date

2021-06-01

DOI

10.1016/j.molimm.2021.02.023

Peer reviewed



Published in final edited form as:

Mol Immunol. 2021 June ; 134: 13–24. doi:10.1016/j.molimm.2021.02.023.

Augmented Th17-stimulating activity of BMDCs as a result of reciprocal interaction between $\gamma\delta$ and dendritic cells

Deming Sun^{a,*}, Minhee K. Ko^a, Hui Shao^b, Henry J. Kaplan^c

^aDoheny Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90033, United States

^bDepartment of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, KY, 40202, United States

^cSaint Louis University (SLU) Eye Institute, SLU School of Medicine, Saint Louis, MO, 63104, United States

Abstract

Our previous studies demonstrated that $\gamma\delta$ T cells have a strong regulatory effect on Th17 autoimmune responses in experimental autoimmune uveitis (EAU). In the current study, we show that reciprocal interactions between mouse $\gamma\delta$ T cells and dendritic cells (DCs) played a major role in $\gamma\delta$ regulation of Th17 responses. Mouse bone marrow-derived dendritic cells (BMDCs) acquired an increased ability to enhance Th17 autoimmune responses after exposure to $\gamma\delta$ T cells; meanwhile, after exposure, a significant portion of the BMDCs expressed CD73 – a molecule that is fundamental in the conversion of immunostimulatory ATP into immunosuppressive adenosine. Functional studies showed that CD73⁺ BMDCs were uniquely effective in stimulating the Th17 responses, as compared to CD73⁻ BMDCs; and activated $\gamma\delta$ T cells are much more effective than non-activated $\gamma\delta$ T cells at inducing CD73⁺ BMDCs. As a result, activated $\gamma\delta$ T cells acquired greater Th17-enhancing activity. Treatment of BMDCs with the CD73-specific antagonist APCP abolished the enhancing effect of the BMDCs. $\gamma\delta$ T cells more effectively induced CD73⁺ BMDCs from the BMDCs that were pre-exposed to TLR ligands, and the response was further augmented by adenosine. Moreover, BMDCs acquired increased ability to stimulate $\gamma\delta$ activation after pre-exposure to TLR ligands and adenosine. Our results demonstrated that both extra-cellular adenosine and TLR ligands are critical factors in augmented Th17 responses in this autoimmune disease, and the reciprocal interactions between $\gamma\delta$ T cells and DCs play a major role in promoting Th17 responses.

Keywords

Adenosine; Autoimmunity; Adenosine receptors; APCP; BMDCs; CD73; EAU $\gamma\delta$ T cells

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Corresponding author at: Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90033, United States. dsun@doheny.org (D. Sun).

Declaration of Competing Interest

None of the authors have any conflict of interest pertaining to this work.

1. Introduction

$\gamma\delta$ T cells can either enhance (Nian et al., 2011; Rajan et al., 2000; Spahn et al., 1999) or inhibit (Born et al., 1999; D'Souza et al., 1997; Liang et al., 2016a) an immune response. Clarifying the mechanism by which they function should allow us to manipulate immune responses more effectively. Our previous studies on the pathogenesis of experimental autoimmune uveitis (EAU) revealed that the regulatory effects of $\gamma\delta$ T cells were closely associated with the activation status of the cells; and that activated $\gamma\delta$ T cells have a greater enhancing effect on Th17 responses (Liang et al., 2013b, b; Liang et al., 2016a; Nian et al., 2011). In determining the factors attributed to $\gamma\delta$ T cell activation that lead to augmented Th17 responses, our early studies showed that the regulatory effect of $\gamma\delta$ T cells is adenosine-dependent and that interrelated $\gamma\delta$ - and adenosine-mediated regulations are co-contributors (Liang et al., 2014a, b, 2015; Liang et al., 2016a). Adenosine showed a significant augmenting effect in $\gamma\delta$ T cell activation, by which it enhances Th17 autoimmune responses (Liang et al., 2018, 2014b, a; Liang et al., 2016b).

Various pathological conditions are accompanied by ATP release from the intracellular to the extracellular compartment. Indeed, all mammalian cells are capable of releasing ATP (Eltzschig et al., 2004; Junger, 2011; Piccini et al., 2008; Schenk et al., 2008; Yip et al., 2009). Adenosine accumulates at inflamed sites as the result of ATP release into the extracellular environment, following dephosphorylation to ADP and AMP, and a terminal reaction converting AMP to adenosine (Sitkovsky et al., 2004; Sitkovsky and Ohta, 2005). The increase of extracellular ATP and its metabolites exerts a strong modulatory effect on immune responses and inflammation. Adenosine is an important regulatory molecule of immune responses and it affects functions of many types of immune cells, including T cells (Jin et al., 2010; Lappas et al., 2005), macrophages/DCs (Lappas et al., 2005; Naganuma et al., 2006; Panther et al., 2001), NK cells (Hoskin et al., 2008), neutrophils (Fredholm et al., 2001), platelets (Varani et al., 1996), and regulatory T cells (Ehrentraut et al., 2012; Naganuma et al., 2006; Zarek et al., 2008). During inflammation or under ischemic conditions, generation of increased amounts of adenosine in the extracellular environment modulates various biological responses, including immune responses (Fredholm et al., 2011; Haskó et al., 2008; Jacobson and Gao, 2006; Sauer et al., 2012).

Activation of autoreactive T cells is a key event by which T cells cause tissue damage and inflammation; and dendritic cells (DCs) are key cell elements causing T cell activation (Steinman et al., 1983) (Guermontprez et al., 2002). To determine whether $\gamma\delta$ T cell regulation involves DC functional modulation, we examined the antigen-presenting (AP) effect of bone marrow-derived dendritic cells (BMDCs) on Th17 autoreactive T cells, before and after exposure to $\gamma\delta$ T cells. We were able to show that the acquisition of augmented Th17-stimulating activity was closely associated with an increased appearance of a CD73⁺ BMDCs among the $\gamma\delta$ T cell-exposed BMDCS and that this activity was barely detectable before $\gamma\delta$ T cell exposure. Comparative studies on the AP functions of BMDCs to Th1 and Th17 autoreactive T cells, before and after exposure to $\gamma\delta$ T cells, showed that the BMDCs acquired a greater stimulating effect of Th17 responses after a pre-exposure to $\gamma\delta$ T cells; whereas after a pre-exposure to $\alpha\beta$ T cells, the BMDCs acquired a greater stimulating effect of Th1 responses. Subsequent studies showed that

separated CD73⁺ and CD73⁻ BMDCs are functionally distinct in promoting Th1- and Th17-responder T cells, and in cytokine production, including IL-12, IL-23, IL-6, and IL-1 β . We also show that significantly increased numbers of CD73⁺ BMDCs could be obtained if BMDCs were pre-treated with a TLR ligand before interacting with $\gamma\delta$ T cells; addition to cultures with adenosine further augmented the response. Our results demonstrated that extracellular adenosine and TLR ligands are critical factors in augmented Th17 responses in this autoimmune disease. Reciprocal interaction between $\gamma\delta$ T cells and DCs is an important pathway by which $\gamma\delta$ T cells regulate immune responses; and generation of an increasing number of CD73⁺ DCs is a pathogenic event leading to augmented Th17 autoimmune responses.

2. Results

2.1. Th17-promoting activity of BMDCs was enhanced after incubation with $\gamma\delta$ T cells

Our previous studies demonstrated that $\gamma\delta$ T cells have a stronger regulatory effect on Th17 responses than on Th1 responses (Cui et al., 2009; Liang et al., 2013b, a; Nian et al., 2011). To determine the underlying mechanisms, we questioned whether the antigen-presenting function of DCs would be altered through the effect of $\gamma\delta$ T cells. Using mouse BMDCs cultured from GM-CSF and IL-4-containing medium (Chen et al., 2015; Liang et al., 2015), we examined the phenotypic and functional alterations of BMDCs before and after exposure to $\gamma\delta$ T cells at a pre-determined optimal ratio of T: DC = 1:20; control sets included BMDCs exposed to the same numbers of $\alpha\beta$ T cells.

After a 24 h co-culture, the interacting T cells were removed and the BMDCs were collected, irradiated and seeded on to 24-well plates (5×10^5 /well). Responder T cells isolated from immunized B6 mice were then added. Assessment of antigen-specific Th1 and Th17 responses were set by stimulation of responder T cells by immunizing antigen (IRBP₁₋₂₀) at a T: DC ratio of 1:20, under Th1- or Th17-polarizing conditions as we previously reported (Liang et al., 2013b; Peng et al., 2007). The AP function of BMDCs was assessed by measuring proportional IFN- γ ⁺ and IL-17⁺ T cells among responder T cells (Cui et al., 2009; Liang et al., 2013b, a; Nian et al., 2011) and cytokine production in supernatants of responder T cells. Fig. 1 shows that BMDCs stimulated a significantly greater of IL-17⁺ cells among responder T cells when they were tested after co-culture with $\gamma\delta$ T cells, compared to control BMDCs cultured in the absence of $\gamma\delta$ T cells (Fig. 1A lower middle panel); however, their capacity to stimulate Th1 responses (or IFN- γ ⁺ T cells) was not significantly affected (Fig. 1A upper middle panels). Control BMDCs also included a group of BMDCs pre-exposed to the same number of $\alpha\beta$ T cells. The BMDCs in this group stimulated a greater number of IFN- γ ⁺ cells among the responder T cells (Fig. 1A, upper right panel), but not IL-17⁺ T cells (Fig. 1A, upper lower panel). Cytokine tests agreed evaluating IFN- γ ⁺ and IL-17⁺ T cell numbers by showing that the $\gamma\delta$ T cell-exposed BMDCs stimulated significantly greater amounts of IL-17 but not IFN- γ from responder T cells from four separate assays (Fig. 1B); whereas the $\alpha\beta$ T cells-exposed BMDCs stimulated greater amounts of IFN- γ but not IL-17 from the responder T cells (Fig. 1C).

2.2. Increased appearance of CD73⁺ DCs among the $\gamma\delta$ -exposed BMDCs

To determine the cellular and molecular mechanisms by which $\gamma\delta$ shaped the AP function of BMDCs, we examined the expression of T cell activation surface molecules on BMDCs to both before and after exposure to $\gamma\delta$ T cells. Our results showed that the $\gamma\delta$ -exposed BMDCs expressed increased levels of CD86 (Fig. 2A) and CD73 (Fig. 2B), but not MHC II molecules (Fig. 2A); by contrast, $\alpha\beta$ -exposed BMDCs expressed increased levels of MHC II molecules but not CD86 and CD73 (Fig. 2A). Examination of CD73 was included because our previous observations showed that extracellular adenosine levels and CD73 molecules expressed on immune cells were crucially involved in Th17 responses (Liang et al., 2014a, b, 2015; Liang et al., 2016a). We observed, unexpectedly, that a significant portion of the BMDCs co-expressed CD73 after exposure to $\gamma\delta$ T cells, whereas the untreated BMDCs as well as those exposed to $\alpha\beta$ T cells remained CD73 negative (Fig. 2B). Cytokine-production tests showed that $\gamma\delta$ -exposed BMDCs produced significantly increased amounts of IL-23 and IL-1 β , whereas $\alpha\beta$ -exposed BMDCs produced significantly increased amounts of IL-12 (Fig. 2C).

To determine whether CD73 expression on BMDCs was related to their Th1- and Th17-stimulating effect, we separated CD73⁺ and CD73⁻ BMDCs using a MACS column (Fig. 3A). The AP function (Fig 3B) and cytokine-producing activity (Fig. 3C) of separated CD73⁻ and CD73⁺ BMDCs was determined both before and after exposure to $\gamma\delta$ T cells. The results showed that CD73⁺ BMDCs stimulated a significantly greater number of IL-17⁺ autoreactive T cells after exposure to $\gamma\delta$ T cells, whereas CD73⁻ BMDCs did not. Measurement of cytokine-producing capability of CD73⁺ and CD73⁻ BMDCs, after LPS stimulation and in the absence or presence of AMP, showed that under LPS stimulation CD73⁻ BMDCs produced even more IL-12 and IL-23 as compared to CD73⁺ BMDCs. However, after addition of AMP only CD73⁺, but not CD73⁻, BMDCs produced significantly higher amounts of IL-23 (Fig 3C, right panels). IL-12 production was the opposite. AMP inhibited IL-12 production by CD73⁺, but not CD73⁻, BMDCs (Fig 3C, left panels) suggesting that CD73 expression affected BMDC responses to AMP. Since CD73 degrades AMP to adenosine, enhanced IL-23 cytokine production by CD73⁺ BMDCs leads to augmented Th17 responses. To further determine whether CD73 is the functional molecule responsible for BMDCs' selective Th1- and Th17-stimulating activity, we also examined the AP function of $\gamma\delta$ -exposed CD73^{+/+} BMDCs, with or without treatment with APCP – an antagonist that specifically blocks CD73 function (Jin et al., 2010; Liang et al., 2014b). As demonstrated in Fig. 3D, APCP treatment completely abolished augmented Th17 responses by $\gamma\delta$ -treated BMDCs.

We questioned whether BMDCs isolated from CD73^{-/-} mice (CD73^{-/-} BMDCs) were functionally different from those isolated from wt-B6 mice (CD73^{+/+} BMDCs). Fig. 4A demonstrated that the Th17-stimulating function of CD73^{+/+} and CD73^{-/-} BMDCs (lower panels compared to the upper panels) were indistinguishable before exposure to $\gamma\delta$ T cells. After interacting with $\gamma\delta$ T cells, the Th17-promoting effect of CD73^{+/+} BMDCs was much greater increased, even though minimal increased Th17 promoting effect were also seen in CD73^{-/-} BMDCs. The effect on Th1 responses showed no difference with either CD73^{+/+} or CD73^{-/-} BMDCs (Fig. 4B). Indeed, measurement of cytokine production by responder

T cells under the same experimental setting supported this conclusion by showing that the Th17 responses stimulated by CD73^{+/+} BMDCs was augmented by addition of AMP and partially blocked by APCP (upper panels), whereas the Th17 responses stimulated by CD73^{-/-} BMDCs was not augmented by addition of AMP (lower panels) (Fig. 4C).

2.3. Role of adenosine in $\gamma\delta$ -DC interaction

Given previous findings (Antonioli et al., 2013; Ben Addi et al., 2008; Novitskiy et al., 2008; Yang et al., 2009), including those of our own studies (Chen et al., 2015; Liang et al., 2015), that adenosine metabolism has a great impact on DC differentiation and function, we examined the role of adenosine in $\gamma\delta$ -DC interaction. Adenosine deaminase (ADA) is an enzyme that converts adenosine into functionally inactive molecules (North and Cohen, 1978; Ullman et al., 1976). We previously reported that administration of a single dose of ADA to EAU-prone B6 mice inhibited the Th17 pathogenic T cell responses, as well as the development of EAU (Liang et al., 2016b). To determine whether depletion of an excessive amount of endogenously generated adenosine by ADA would modulate $\gamma\delta$ -DC interaction, and thus, prevent augmented Th17 responses we examined the AP function of $\gamma\delta$ -exposed BMDCs, with or without prior treatment with ADA. As demonstrated in Fig. 5A&B, approximately 50 % of the Th17-enhancing effect of the BMDCs induced by pre-exposure to $\gamma\delta$ T cells was reduced by pretreatment with ADA, as measured by IL-17⁺ T cell responses among responder T cells. Administration of 1 U/mL of ADA was effective in *in vitro* tests, while a further increase in the ADA dose did not further increase the blocking effect (not shown).

2.4. Activated $\gamma\delta$ T cells were more active in inducing CD73⁺ BMDCs

Given our previous finding that activated $\gamma\delta$ T cells strongly enhance Th17 responses (Liang et al., 2017, 2013b; Nian et al., 2011), we wished to determine whether activated $\gamma\delta$ T cells more effectively induce CD73⁺ BMDCs, leading to augmented Th17 responses. Activated and non-activated $\gamma\delta$ T cells were isolated from immunized and naïve B6 mice, as our previous studies showed that a majority (>60 %) of the $\gamma\delta$ T cells in immunized mice were activated, whereas those in naïve mice remain non-activated (Liang et al., 2013b, a). Our results showed that the BMDCs pre-exposed to activated $\gamma\delta$ T cells had a much greater effect in inducing CD73⁺ BMDCs. The stronger promoting effect was most easily demonstrated with a low $\gamma\delta$ /BMDCs ratios. As demonstrated in Fig. 5C, CD73⁺ BMDCs increased >20-fold after exposure to $\gamma\delta$ T cells. When the ratio of $\gamma\delta$ /BMDCs declined to 1:20, however, activated $\gamma\delta$ T cells remained functionally potent, whereas the effect of resting $\gamma\delta$ T cells declined dramatically.

2.5. Reciprocal interactions between BMDCs and $\gamma\delta$ T cells

$\gamma\delta$ T cells can be activated in the absence of TCR ligation (Petermann et al., 2010; Rincon-Orozco et al., 2005; Sutton et al., 2009; Wesch et al., 2006). They can be activated by cytokines including IL-1 β , IL-7, and IL-23 (Nian et al., 2011; Petermann et al., 2010; Sutton et al., 2009), TLR ligands (Nian et al., 2011), and DCs (Liang et al., 2012, 2013a; Liang et al., 2013b). To examine whether the $\gamma\delta$ -stimulating effect of BMDCs was affected by inflammatory molecules like TLR ligands and adenosine, BMDCs were tested for their stimulating effect on $\gamma\delta$ T cells, with or without prior treatment with TLR ligand and/or

adenosine. CD3⁺ T cells isolated from immunized B6 mice were taken as responder T cells. After a two-day incubation, the proportional number of $\alpha\beta$ and $\gamma\delta$ T cells in the responder T cells were assessed. As demonstrated in Fig. 6, BMDCs have a weak stimulating effect on $\gamma\delta$ T cell expansion before exposure to TLR ligands. After exposure to TLR ligands, the stimulating effect increased significantly (13.1 % versus 4.8 % of $\gamma\delta$ T cells) and was further increased (from 13.1 to 27.2%) when BMDCs received prior exposure of both TLR ligand and adenosine.

3. Discussion

Multiple lines of evidence demonstrated that $\gamma\delta$ T cells have a regulatory effect on immune responses (Chien et al., 2014; Girardi, 2006; Huber et al., 2000; Kabelitz et al., 2007; Paul et al., 2014; Poccia et al., 2005). We have previously shown that $\gamma\delta$ T cells have a strong regulatory effect on Th17 responses in autoimmune disease, and that this effect is determined by the activation status of $\gamma\delta$ T cells (Cui et al., 2009; Liang et al., 2013b, a; Nian et al., 2011, 2010). In this study, we examined the regulatory mechanisms of $\gamma\delta$ T cells; determined the underlying mechanisms by which activation shapes the $\gamma\delta$ T cells' regulatory activity; and determined the mechanism by which $\gamma\delta$ T cells distinctively affect Th17 and Th1 responses (Cui et al., 2009; Liang et al., 2013b, a; Nian et al., 2011, 2010). We show that interaction between $\gamma\delta$ T cells and DCs is an important pathway to promote Th17 responses. BMDCs cultured in the prototypic GM-CSF + IL-4-containing medium were superior APCs for Th1 responses, but not as effective at Th17 responses. However, after exposure to $\gamma\delta$ T cells, they became strongly effective in stimulating Th17 responses. Such an observation increases our understanding of the role of DCs in the balance between Th1 and Th17 responses in pathogenic disease processes.

The results of examining the phenotypic and functional changes in BMDCs, before and after exposure to $\gamma\delta$ T cells, showed that the increased Th17-promoting activity after exposure to $\gamma\delta$ T cells was closely associated with the appearance of CD73⁺ BMDCs, and that this enhancing activity was greatly diminished when BMDCs received prior treatment with the CD73 antagonist APCP (26). These results suggest that the enhanced Th17-promoting activity of BMDC on $\gamma\delta$ T cells in autoimmune responses is attributed to generation of inducible CD73⁺ DCs. The fact that activated $\gamma\delta$ T cells are much better able to induce CD73⁺ BMDCs, thereby leading to augmented autoimmune responses, supported our previous findings (Liang et al., 2013b, b; Liang et al., 2016a; Nian et al., 2011).

The purinergic system is an evolutionally selected regulatory system that modulates immune responses (Hasko et al., 2008; Junger, 2011). Release of ATP into the extracellular space is elicited by tissue injury or damage, such as that related to inflammation. Under physiological conditions ATP is present primarily within cells. Almost all mammalian cell types are capable of releasing ATP in response to tissue injury or damage (Junger, 2011). Once released into the extracellular space ATP is hydrolyzed in a stepwise manner into ADP, AMP, and finally adenosine, by ectonucleotidases, including CD73 and CD39, which are expressed on surfaces of various immune and non-immune cells (Doherty et al., 2012; Raczkowski et al., 2018; Sidibé and Imhof, 2015; Yegutkin, 2008). The regulatory effect of

adenosine on immune responses has been well established (Augusto et al., 2013; Csoka et al., 2008; Ibrahim et al., 2011; Jacobson and Gao, 2006).

Our attention to the study of adenosine's effect on $\gamma\delta$ regulation was prompted by reports that this molecule affects the immune function of a wide range of cells, such as lymphocytes (Jin et al., 2010; Lappas et al., 2005; Wilson et al., 2011), polymorphonuclear leukocytes (Fredholm et al., 2001; Hasko and Cronstein, 2004), and macrophages/DCs (Hasko et al., 2009; Lappas et al., 2005; Naganuma et al., 2006; Panther et al., 2001). The outcome of those studies suggested that adenosine analogues suppress Th1 responses. Indeed, such a suppressive effect of adenosine has been exploited in initiating immunotherapies for cancer (Antonioli et al., 2013; Vijayan et al., 2017) and autoimmune diseases (Cronstein et al., 1993; Eckle et al., 2008; Flogel et al., 2012; Hasko et al., 2008; Ibrahim et al., 2011; Jacobson and Gao, 2006; Luijk et al., 2008). Since previous studies examining adenosine's effect on immune responses have not adequately examined Th17 responses, we wished to determine whether existing findings of the adenosine effect on immune responses would apply to Th17 responses as well. Using a reproducible EAU model, our recent studies showed that Th17 pathogenic responses differed greatly in their response to (Liang et al., 2018, 2014b) $\gamma\delta$ - and adenosine-mediated regulation when compared to Th1 pathogenic responses. Unlike previous observations that adenosine was mainly inhibitory in Th1 responses, its effect on Th17 responses is often enhancing (Liang et al., 2014b).

We have previously demonstrated that adenosine played an important role in skewing DC differentiation (Chen et al., 2015; Liang et al., 2015; Zhao et al., 2016). Since CD73 is pivotal in the conversion of ATP into adenosine (Beavis et al., 2012; Rabinovich et al., 2007), and since immune cells that express different levels of CD73 are functionally distinct (Naganuma et al., 2006; Zarek et al., 2008), we wished to determine whether adenosine affected $\gamma\delta$ -DC interaction. Our results showed that prior treatment of BMDCs with ADA - an enzyme that degrades adenosine into functionally inactive molecules (North and Cohen, 1978; Ullman et al., 1976), diminished the Th17-stimulating activity of BMDCs, indicating that adenosine is crucially involved in the regulatory function of $\gamma\delta$ T cells (Liang et al., 2014b, 2015; Liang et al., 2016a).

In summary, our studies demonstrated that the $\gamma\delta$ T cell-mediated immunoregulation is strongly affected by reciprocal interactions between adenosine- and $\gamma\delta$ T cells. $\gamma\delta$ T cell stimulated DCs have a greater ability to promote Th17 pathogenic T cell responses. After exposure to TLR ligand and adenosine BMDCs acquired increased $\gamma\delta$ -stimulating effect, and thus, promoted $\gamma\delta$ activation. Furthermore, both TLR ligands and extracellular adenosine appear to play an important role in the balance of Th1 and Th17 pathogenic responses with their reciprocal interactions leading to augmented autoimmune responses.

4. Conclusion

In this study we present experimental evidence that mouse bone marrow-derived dendritic cells (BMDCs) acquired an increased ability to enhance Th17 autoimmune responses after exposure to $\gamma\delta$ T cells; meanwhile, after exposure, a significant portion of the BMDCs expressed CD73 – a molecule that is fundamental in the conversion of immunostimulatory

ATP into immunosuppressive adenosine. CD73⁺ BMDCs were uniquely effective in stimulating the Th17 responses, as compared to CD73⁻ BMDCs and treatment of BMDCs with the CD73-specific antagonist APCP abolished the enhancing effect of the BMDCs. Moreover, BMDCs acquired increased ability to stimulate $\gamma\delta$ activation after pre-exposure to TLR ligands and adenosine and the reciprocal interactions between $\gamma\delta$ T cells and DCs play a major role in promoting Th17 responses.

5. Materials and methods

5.1. Animals and reagents

Female C57BL/6 (B6) mice were purchased from Jackson Laboratory (Bar Harbor, ME); 12- to 16-week-old mice were used in all studies. CD73^{-/-} knockout mice obtained from Jackson Laboratory are available in our laboratory (Liang et al., 2016a). All mice were housed and maintained in the animal facilities of the University of California Los Angeles. Institutional approval (Protocol number: ARC#2014-029-03A) was obtained from the Institutional Animal Care and Use Committee of the Doheny Eye Institute, University of California Los Angeles, and institutional guidelines regarding animal experimentation were followed. Veterinary care was provided by IACUC faculty. Any immunized animal that displayed joint swelling was either humanely euthanized or administered an analgesic (buprenorphine, 0.1 mg/kg sc. twice daily or ketoprofen, 5 mg/kg sc. daily) until the swelling resolved. By the end of the study, mice were euthanized by cervical dislocation after a lethal injection of ketamine and xylazine before tissue collection.

Recombinant murine IL-12 and IL-23 were purchased from R & D Systems (Minneapolis, MN). FITC-, PE- or allophycocyanin-conjugated antibodies against the mouse $\alpha\beta$ TCR, IFN- γ , IL-17, Foxp3 and isotype control antibodies were purchased from e-Bioscience (San Diego, CA). ATP was purchased from Sigma-Aldrich (St. Louis, MO). The non-selective AR agonist 50-N-ethylcarboxamidoadenosine (NECA) (Csóka et al., 2012; Ryzhov et al., 2011) and the CD73 inhibitor α , β -methylene ADP (APCP) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

5.2. Prepare $\gamma\delta$ T cells

Non-activated and activated $\gamma\delta$ T cells were separated from either naïve B6 mice or IRBP₁₋₂₀-immunized B6 mice, respectively (Liang et al., 2013b, a), by positive selection using a combination of FITC-conjugated anti-TCR- δ antibody and anti-FITC antibody-coated Microbeads, followed by separation using an auto-MACS.

5.3. Prepare autoreactive T cells from mice immunized with autoantigen (IRBP₁₋₂₀)

B6 mice were subcutaneously injected with an emulsion containing 200 μ g of the human interphotoreceptor retinoid-binding protein (IRBP) peptide (IRBP₁₋₂₀, Sigma-Aldrich) in PBS and CFA (Difco, Detroit, MI) at 6 spots at the tail base and on the flank, followed by i.p. injection of 300 ng of pertussis toxin. $\alpha\beta$ T cells used were purified from the spleen or draining lymph nodes of immunized mice at day 13 post-immunization using an auto-MACS separator system, as described previously [29]. The purity of the purified cells was >95 %, as determined by flow cytometric analysis using PE-conjugated antibodies

against $\alpha\beta$ T cells. The cells were co-cultured for 48 h with irradiated (5000 Rad) spleen cells (1.5×10^6 /well) as APCs and IRBP₁₋₂₀ (10 μ g/mL) in a 24-well plate under either Th1 (culture medium supplemented with 10 ng/mL of IL-12) or Th17 polarized conditions (culture medium supplemented with 10 ng/mL of IL-23) (Liang et al., 2013b, a). Cytokine (IFN- γ and IL-17) levels in the serum and 48 h of culture supernatants were measured by ELISA (R & D Systems).

5.4. Intracellular staining and FACS analysis

For intracellular staining, T cells (2×10^5 in 100 μ l of PBS) harvested 5 days post in vitro stimulation with the immunizing peptide and APCs were incubated for 4 h with 50 ng/mL of PMA, 1 μ g/mL of ionomycin, and 1 μ g/mL of brefeldin A (Sigma-Aldrich), then were washed, fixed, permeabilized overnight with Cytotfix/Cytoperm buffer (eBioscience), intracellularly stained with antibodies against IFN- γ and IL-17, and analyzed on a FACS_{calibur} flow cytometer.

5.5. Generation of BMDCs

BMDCs were generated by incubation of bone marrow cells for 5 days in the presence of 10 ng/mL of recombinant murine GM-CSF and IL-4 (R&D Systems), as described previously (Inaba et al., 1992). Cytokine (IL-1, IL-6, IL-12 and IL-23) levels in the culture medium were measured by ELISA. To determine antigen-presenting function, BMDCs were incubated in a 24-well plate with responder T cells isolated from immunized B6 mice under Th1- or Th17-polarizing conditions. Forty-eight hours after stimulation, IFN- γ and IL-17 in the culture medium were measured by ELISA. The percentage of IFN- γ^+ and IL-17 $^+$ T cells among the responder T cells was determined by intracellular staining after 5 days of culture as described above.

5.6. Experimental setting for T cell-dendritic cell interaction and measurement of Th1 and Th17 responses

In 6-well plates, 2×10^6 /well BMDCs were co-cultured with 2×10^5 /well $\gamma\delta$ or $\alpha\beta$ T cells at a ratio of T: DC = 1:10. The T cells were removed after 24 h and the collected BMDCs were irradiated (5000 Rad), recounted, and seeded to a 24-well plate (3×10^4 /well). Responder CD3 $^+$ cells (1×10^6 /well) isolated from immunized TCR- $\delta^{-/-}$ mice were then added. Five days later, the percentage of IFN- γ^+ and IL-17 $^+$ T cells among the responder T cells was determined after an intracellular staining followed by FACS analysis, as described previously (Liang et al., 2014a).

5.7. ELISA measurement of cytokine

ELISA kits (E-Bioscience) were used to measure serum IFN- γ and IL-17 levels on day 13 post-immunization and in the 48 h culture supernatants of responder T cells isolated from IRBP₁₋₂₀-immunized B6 or TCR- $\delta^{-/-}$ mice on day 13 post-immunization. Purified CD3 $^+$ T cells from IRBP₁₋₂₀-immunized TCR- $\delta^{-/-}$ mice were stained with CFSE (Sigma-Aldrich) as described previously. Briefly, the cells were washed and suspended at 50×10^6 cells/mL in serum-free RPMI 1640 medium; incubated at 37 °C for 10 min with gentle shaking with a final concentration of 5 μ M CFSE; then washed twice with, and suspended in, complete

medium, stimulated with immunizing peptide in the presence of APCs, and analyzed by flow cytometry.

5.8. Statistical analysis

The results in the figures are from a representative experiment, which was repeated 3–5 times. The statistical significance of differences between groups in a single experiment was initially analyzed by ANOVA, and, if a statistical significance was detected, the Student–Newman–Keuls post-hoc test was subsequently used. A P value less than 0.05 was considered statistically significant (indicated as **).

Acknowledgement

This work was supported by U.S. National Institutes of Health, National Eye Institute Grants EY0022403 and EY018827 and grant from for Research to Prevent Blindness, NYC. The authors declare no conflicts of interest.

Abbreviations:

AR	adenosine receptor
ATP	adenosine triphosphate
A2AR	adenosine 2A receptor
APCP	α,β -methylene adenosine 5'-diphosphate
EAU	experimental autoimmune uveitis
IRBP	interphotoreceptor retinoid-binding protein
NECA	5'-N- ethylcarboxamidoadenosine

References

- Antonioli L, Blandizzi C, Pacher P, Hasko G, 2013. Immunity, inflammation and cancer: a leading role for adenosine. *Nat. Rev. Cancer* 13, 842–857. [PubMed: 24226193]
- Augusto E, Matos M, Sevigny J, El-Tayeb A, Bynoe MS, Muller CE, Cunha RA, Chen JF, 2013. Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. *J. Neurosci* 33, 11390–11399. [PubMed: 23843511]
- Beavis PA, Stagg J, Darcy PK, Smyth MJ, 2012. CD73: a potent suppressor of antitumor immune responses. *Trends Immunol.* 33, 231–237. [PubMed: 22487321]
- Ben Addi A, Lefort A, Hua X, Libert F, Communi D, Ledent C, Macours P, Tilley SL, Boeynaems J-M, Robaye B, 2008. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A2B receptor. *Eur. J. Immunol* 38, 1610–1620. [PubMed: 18465770]
- Born W, Cady C, Jones-Carson J, Mukasa A, Lahn M, O'Brien R, 1999. Immunoregulatory functions of $\gamma\delta$ T cells. *Adv. Immunol* 71, 77–144. [PubMed: 9917911]
- Chen M, Liang D, Zuo A, Shao H, Kaplan HJ, Sun D, 2015. An A2B adenosine receptor agonist promotes Th17 autoimmune responses in experimental autoimmune uveitis (EAU) via dendritic cell activation. *PLoS One* 10, e0132348. [PubMed: 26147733]
- Chien Y.-h., Meyer C, Bonneville M, 2014. $\gamma\delta$ T Cells: First line of defense and beyond. *Ann. Rev. Immunol* 32, 121–155. [PubMed: 24387714]

- Cronstein BN, Naime D, Ostad E, 1993. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. *J. Clin. Invest* 92, 2675–2682. [PubMed: 8254024]
- Csoka B, Himer L, Selmezy Z, Vizi ES, Pacher P, Ledent C, Deitch EA, Spolarics Z, Nemeth ZH, Hasko G, 2008. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. *FASEB J.* 22, 3491–3499. [PubMed: 18625677]
- Csóka B, Selmezy Z, Koscsó B, Németh ZH, Pacher P, Murray PJ, Kepka-Lenhart D, Morris SM, Gause WC, Leibovich SJ, et al. , 2012. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. *FASEB J.* 26, 376–386. [PubMed: 21926236]
- Cui Y, Shao H, Lan C, Nian H, O'Brien RL, Born WK, Kaplan HJ, Sun D, 2009. Major role of $\gamma\delta$ T cells in the generation of IL-17⁺ uveitogenic T cells. *J. Immunol* 183, 560–567. [PubMed: 19542467]
- D'Souza CD, Cooper AM, Frank AA, Mazzaccaro RJ, Bloom BR, Orme IM, 1997. An anti-inflammatory role for $\gamma\delta$ T lymphocytes in acquired immunity to mycobacterium tuberculosis. *J. Immunol* 158, 1217–1221. [PubMed: 9013962]
- Doherty GA, Bai A, Hanidziar D, Longhi MS, Lawlor GO, Putheti P, Csizmadia E, Nowak M, Cheifetz AS, Moss AC, et al. , 2012. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. *Eur. J. Immunol* 42, 3062–3072. [PubMed: 22965858]
- Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK, 2008. A2B adenosine receptor dampens hypoxia-induced vascular leak. *Blood* 111, 2024–2035. [PubMed: 18056839]
- Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, Colgan SP, 2004. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. *Blood* 104, 3986–3992. [PubMed: 15319286]
- Flogel U, Burghoff S, van Lent PL, Temme S, Galbarz L, Ding Z, El-Tayeb A, Huels S, Bonner F, Borg N, et al. , 2012. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. *Sci. Transl. Med* 4, 146ra108.
- Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J, 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol. Rev* 53, 527–552. [PubMed: 11734617]
- Girardi M, 2006. Immunosurveillance and immunoregulation by $\gamma\delta$ T cells. *J. Invest. Dermatol* 126, 25–31. [PubMed: 16417214]
- Guermontprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S, 2002. Antigen presentation and T cell stimulation by dendritic cells. *Annu. Rev. Immunol* 20, 621–667. [PubMed: 11861614]
- Hasko G, Cronstein BN, 2004. Adenosine: an endogenous regulator of innate immunity. *Trends Immunol.* 25, 33–39. [PubMed: 14698282]
- Hasko G, Linden J, Cronstein B, Pacher P, 2008. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat. Rev. Drug Discov* 7, 759–770. [PubMed: 18758473]
- Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P, 2009. A2B adenosine receptors in immunity and inflammation. *Trends Immunol.* 30, 263–270. [PubMed: 19427267]
- Huber SA, Graveline D, Newell MK, Born WK, O'Brien RL, 2000. V γ 1+ T cells suppress and V γ 4+ T cells promote susceptibility to coxsackievirus B3-induced myocarditis in mice. *J. Immunol* 165, 4174–4181. [PubMed: 11035049]
- Ibrahim AS, El-shishtawy MM, Zhang W, Caldwell RB, Liou GI, 2011. A2A adenosine receptor (A2AAR) as a therapeutic target in diabetic retinopathy. *Am. J. Pathol* 178, 2136–2145. [PubMed: 21514428]
- Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM, 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J. Exp. Med* 176, 1693–1702. [PubMed: 1460426]
- Jacobson KA, Gao Z-G, 2006. Adenosine receptors as therapeutic targets. *Nat. Rev. Drug Discov* 5, 247–264. [PubMed: 16518376]

- Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B, 2010. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. *Cancer Res.* 70, 2245–2255. [PubMed: 20179192]
- Junger WG, 2011. Immune cell regulation by autocrine purinergic signalling. *Nat. Rev. Immunol* 11, 201–212. [PubMed: 21331080]
- Kabelitz D, Wesch D, He W, 2007. Perspectives of $\gamma\delta$ T cells in tumor immunology. *Cancer Res.* 67, 5–8. [PubMed: 17210676]
- Lappas CM, Rieger JM, Linden J, 2005. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. *J. Immunol* 174, 1073–1080. [PubMed: 15634932]
- Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D, 2012. Role of CD25+ dendritic cells in the generation of Th17 autoreactive T cells in autoimmune experimental uveitis. *J. Immunol* 188, 5785–5791. [PubMed: 22539790]
- Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D, 2013a. Retinoic acid Inhibits CD25+ dendritic cell expansion and $\gamma\delta$ T-cell activation in experimental autoimmune uveitis. *Invest. Ophthalmol. Vis. Sci* 54, 3493–3503. [PubMed: 23611991]
- Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D, 2013b. IL-23 Receptor expression on $\gamma\delta$ T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis. *J. Immunol* 191, 1118–1125. [PubMed: 23797670]
- Liang D, Zuo A, Shao H, Chen M, Kaplan HJ, Sun D, 2014a. Anti-inflammatory or pro-inflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environmental-dependent. *J. Immunol* 193, 5498–5505. [PubMed: 25367119]
- Liang D, Zuo A, Shao H, Chen M, Kaplan HJ, Sun D, 2014b. Roles of the adenosine receptor and CD73 in the regulatory effect of $\gamma\delta$ T cells. *PLoS One* 9, e108932. [PubMed: 25268760]
- Liang D, Zuo A, Shao H, Chen M, Kaplan HJ, Sun D, 2015. A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c+Gr-1+dendritic cell subset that promotes the Th17 response. *Immun. Inflamm. Dis* 3, 360–373. [PubMed: 26734458]
- Liang D, Zuo A, Zhao R, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D, 2016a. CD73 Expressed on $\gamma\delta$ T cells shapes their regulatory effect in experimental autoimmune uveitis. *PLoS One* 11, e0150078. [PubMed: 26919582]
- Liang D, Zuo A, Zhao R, Shao H, Kaplan HJ, Sun D, 2016b. Regulation of adenosine deaminase on induced mouse experimental autoimmune uveitis. *J. Immunol* 196, 2646–2654. [PubMed: 26856700]
- Liang D, Nian H, Shao H, Kaplan HJ, Sun D, 2017. Functional Conversion and dominance of $\gamma\delta$ T subset in mouse experimental autoimmune uveitis. *J. Immunol* 198, 1429–1438. [PubMed: 28069804]
- Liang D, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D, 2018. High level expression of A2ARs is required for the enhancing function, but not for the inhibiting function, of gammadelta T cells in the autoimmune responses of EAU. *PLoS One* 13, e0199601. [PubMed: 29928041]
- Luijk B, van den Berge M, Kerstjens HA, Postma DS, Cass L, Sabin A, Lammers JW, 2008. Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. *Allergy* 63, 75–80. [PubMed: 17944983]
- Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB, 2006. Cutting edge: critical role for A2A adenosine receptors in the t cell-mediated regulation of colitis. *J. Immunol* 177, 2765–2769. [PubMed: 16920910]
- Nian H, Shao H, Zhang G, Born WK, O'Brien R, Kaplan HJ, Sun D, 2010. Regulatory effect of $\gamma\delta$ T cells on IL-17⁺ uveitogenic T cells. *Invest. Ophthalmol. Vis. Sci* 51, 4661–4667. [PubMed: 20375337]
- Nian H, Shao H, O'Brien RL, Born WK, Kaplan HJ, Sun D, 2011. Activated $\gamma\delta$ cells promote the activation of uveitogenic T cells and exacerbate EAU development. *Invest. Ophthalmol. Vis. Sci* 52, 5920–5927. [PubMed: 21296823]
- North TW, Cohen SS, 1978. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. *Proc. Natl. Acad. Sci. U. S. A* 75, 4684–4688. [PubMed: 216993]

- Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, et al. , 2008. Adenosine receptors in regulation of dendritic cell differentiation and function. *Blood* 112, 1822–1831. [PubMed: 18559975]
- Panther EL, Idzko M, Herouy Y, Rheinen H, Gebrück-Haerter PJ, Mrowietz U, Dichmann S, Norgauer J, 2001. Expression and function of adenosine receptors in human dendritic cells. *FASEB J.* 15, 1963–1970. [PubMed: 11532976]
- Paul S, Shilpi, Lal G, 2014. Role of $\gamma\delta$ T cells in the autoimmunity. *J. Leukoc. Biol* 97, 295–271.
- Peng Y, Han G, Shao H, Wang Y, Kaplan HJ, Sun D, 2007. Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific t cells in experimental autoimmune uveitis. *Invest. Ophthalmol. Vis. Sci* 48, 4153–4161. [PubMed: 17724201]
- Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S, Prinz I, Hemmer B, Kuchroo VK, Oukka M, et al. , 2010. $\gamma\delta$ T Cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. *Immunity* 33, 351–363. [PubMed: 20832339]
- Piccini A, Carta S, Tassi S, Lasiglié D, Fossati G, Rubartelli A, 2008. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1 β and IL-18 secretion in an autocrine way. *Proc. Natl. Acad. Sci. U. S. A* 105, 8067–8072. [PubMed: 18523012]
- Poccia F, Agrati C, Martini F, Mejia G, Wallace M, Malkovsky M, 2005. V γ 9V δ 2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy. *Immunol. Lett* 100, 14–20. [PubMed: 16115692]
- Rabinovich GA, Gabrilovich D, Sotomayor EM, 2007. Immunosuppressive strategies that are mediated by tumor cells. *Annu. Rev. Immunol* 25, 267–296. [PubMed: 17134371]
- Rackowski F, Rissiek A, Ricklefs I, Heiss K, Schumacher V, Wundenberg K, Haag F, Koch-Nolte F, Tolosa E, Mittrücker H-W, 2018. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to *Listeria monocytogenes*. *PLoS One* 13, e0197151. [PubMed: 29742141]
- Rajan AJ, Asensio VC, Campbell IL, Brosnan CF, 2000. Experimental autoimmune encephalomyelitis on the SJL mouse: effect of $\gamma\delta$ T cell depletion on chemokine and chemokine receptor expression in the central nervous system. *J. Immunol* 164, 2120–2130. [PubMed: 10657666]
- Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T, 2005. Activation of V γ 9V δ 2 T cells by NKG2D. *J. Immunol* 175, 2144–2151. [PubMed: 16081780]
- Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, Dikov MM, Feoktistov I, 2011. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. *J. Immunol* 187, 6120–6129. [PubMed: 22039302]
- Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, Verderio C, Buer J, Scanziani E, Grassi F, 2008. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. *Sci. Signal* 1 ra6. [PubMed: 18827222]
- Sidibé A, Imhof BA, 2015. 5'-Ectonucleotidase/CD73 expression on lymph-circulating lymphocytes and lymphatic endothelial cells offers new paths to explore barrier function. *Eur. J. Immunol* 45, 371–375. [PubMed: 25641680]
- Sitkovsky MV, Ohta A, 2005. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? *Trends Immunol.* 26, 299–304. [PubMed: 15922945]
- Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M, 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. *Annu. Rev. Immunol* 22, 657–682. [PubMed: 15032592]
- Spahn TW, Issazadah S, Salvin AJ, Weiner HL, 1999. Decreased severity of myelin oligodendrocyte glycoprotein peptide 33-35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR δ chain gene. *Eur. J. Immunol* 29, 4060–4071. [PubMed: 10602017]
- Steinman R, Gutchinov B, Witmer MD, Nussenzweig MC, 1983. Dendritic cells are the principal stimulators in primary leukocyte reaction in mice. *J. Exp. Med* 157, 613. [PubMed: 6185614]
- Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG, 2009. Interleukin-1 and IL-23 induce innate IL-17 production from gd t cells, amplifying Th17 responses and autoimmunity. *Immunity* 31, 331–341. [PubMed: 19682929]

- Ullman B, Cohen A, Martin DW Jr, 1976. Characterization of a cell culture model for the study of adenosine deaminase- and purine nucleoside phosphorylase-deficient immunologic disease. *Cell* 9, 205–211. [PubMed: 184961]
- Vijayan D, Young A, Teng MWL, Smyth MJ, 2017. Targeting immunosuppressive adenosine in cancer. *Nat. Rev. Cancer* 17, 709. [PubMed: 29059149]
- Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D, 2006. Direct costimulatory effect of TLR3 ligand poly(I:C) on human $\gamma\delta$ T lymphocytes. *J. Immunol* 176, 1348–1354. [PubMed: 16424161]
- Wilson JM, Kurtz C, Black SG, Ross WG, Alam MS, Linden J, Ernst PB, 2011. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. *J. Immunol* 186, 6746–6752. [PubMed: 21593380]
- Yang M, Ma C, Liu S, Shao Q, Gao W, Song B, Sun J, Xie Q, Zhang Y, Feng A, et al. . 2009. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. *Immunol. Cell Biol* 88, 165–171. [PubMed: 19841638]
- Yegutkin GG, 2008. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* 1783, 673–694. [PubMed: 18302942]
- Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, Junger WG, 2009. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. *FASEB J.* 23, 1685–1693. [PubMed: 19211924]
- Zarek PE, Huang C-T, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD, 2008. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. *Blood* 111, 251–259. [PubMed: 17909080]
- Zhao R, Liang D, Sun D, 2016. Blockade of extracellular ATP effect by oxidized ATP effectively mitigated induced mouse experimental autoimmune uveitis (EAU). *PLoS One* 11, e0155953. [PubMed: 27196432]




Fig. 1. Bone marrow dendritic cells (BMDCs) acquired an enhanced Th17-promoting effect after exposed to $\gamma\delta$ T cells, whereas pre-treatment with $\alpha\beta$ T cells resulted in an augmented Th1-promoting activity.

(A&B) BMDCs were generated by incubation of bone marrow cells for 5 days in GM-CSF and IL-4-containing medium, $\gamma\delta$ T cells and CD3⁺ responder $\alpha\beta$ T cells were prepared from IRBP₁₋₂₀-immunized B6 mice (day 13) by MACS sorting. For pre-treatment of DC with $\gamma\delta$ T cells, 10⁶/well BMDCs were cultured in 6-well plate, with or without $\gamma\delta$ or $\alpha\beta$ T cells, at a T: BMDC ratio of 1:20. The BMDCs were collected after 24 h, irradiated, and re-seeded into 24-well plates. For AP function test, BMDCs, with or without prior exposure to $\alpha\beta/\gamma\delta$ T cells were cocultured with responder T cells in the presence of the immunizing peptide (IRBP₁₋₂₀) and indicated BMDCs. Five days after stimulation, the responder T cells were then double-stained with anti-mouse $\alpha\beta$ TCR and PE-anti-mouse IL-17/IFN- γ and analysed by flow cytometry. Results of four separate assays were pooled and shown (B).

(C) ELISA test of IFN- γ and IL-17 production of the responder T cells activated in the presence of BMDCs with or without exposure to $\gamma\delta$ T cells. Two days after in vitro

stimulation, under either Th1 or Th17 polarized conditions, a fraction of the culture supernatants of the responder T cells were collected for ELISA test. The numbers indicated are calculated from triplicated samples. Data are from a single experiment, representative of three independent experiments. **, $P < 0.05$; ns, not significant.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 2. A significant numbers of bone marrow derived cells (BMDCs) became CD73⁺ after exposure to $\gamma\delta$ T cells.

A) BMDCs were stained for expression of CD86 and MHC class II molecules, with or without a prior exposure to $\gamma\delta$ (middle panels) or $\alpha\beta$ (right panels) T cells.

B) BMDCs were stained for expression of CD73 molecules, with or without prior exposure to $\gamma\delta$ (middle panels) or $\alpha\beta$ (right panels) T cells.

C) Cytokine production by BMDCs without prior exposure to $\gamma\delta$ or $\alpha\beta$ T cells.

The results are from a single experiment (n = 6) and are representative of three independent studies.




Fig. 3. Functional test of separated CD73^{+/+} and CD73^{-/-} BMDCs.

A) Purity test of separated CD73⁺ and CD73⁻ BMDCs. CD11c⁺CD73⁺ and CD11c⁺CD73⁻ BMDCs were separated from $\gamma\delta$ T cell-treated BMDCs, using a MACS-column and dually stained with CD11c and CD73 followed by FACS analysis.

B) Compare AP function of CD73⁺ and CD73⁻ BMDCs. Responder T cells were prepared from IRBP₁₋₂₀-immunized B6 mice. They were stimulated by CD73^{+/+} (left panels) or CD73^{-/-} BMDCs (right panels), with or without a $\gamma\delta$ T cell exposure (detailed in Fig.1 legend), under Th17 polarizing conditions. The responder T cells were then double-stained with anti-mouse $\alpha\beta$ TCR and PE-anti-mouse IL-17/IFN- γ and analysed by flow cytometry.

C) Cytokine-producing ability of separated CD73^{+/+} and CD73^{-/-} BMDCs. CD73^{+/+} and CD73^{-/-} BMDCs were assessed for production of IL-12 and IL-23, before and after treatment with LPS (100 ng/mL) or/and AMP (1 μ M). ** P < 0.05; ns, not significant.

D) Treatment of BMDCs with CD73 specific antagonist APCP abolished the enhancing effect on Th17 responses. AP functions of $\gamma\delta$ -exposed BMDCs were determined with or without a prior treatment of BMDCs with APCP (3 μ M) after BMDCs were exposed to $\gamma\delta$ T cells.




Fig. 4. CD73^{-/-} BMDCs resisted the $\gamma\delta$ -inducing enhancing effect.

A&B) Compared Th1- and Th17-promoting effects of CD73^{+/+} and CD73^{-/-} BMDCs. CD73^{+/+} and CD73^{-/-} BMDCs were isolated from B6 mice and CD73^{-/-} mice, respectively. Responder $\alpha\beta$ T cells were prepared from IRBP₁₋₂₀-immunized B6 mice. AP function of BMDCs was determined, before and after an exposure to $\gamma\delta$ and $\alpha\beta$ T cells, under Th1 (A) and Th17 (B) condition. The results show that the CD73^{-/-} BMDCs have a limited increased Th17-promoting activity after exposure to $\gamma\delta$ T cells, as compared to CD73^{+/+} BMDCs. C) The cytokine assessment of the BMDCs' AP function. Two days in vitro stimulation by CD73^{+/+} (upper panels) or CD73^{-/-} BMDCs (lower panels), under Th17 polarized conditions, and in the presence or absence of AMP, APCP, or AMP plus APCP. Culture supernatants of the responder T cells were collected for ELISA test. **, P < 0.05; ns, not significant.




Fig. 6. BMDCs gained increased $\gamma\delta$ -stimulating activity after treatment with TLR ligand and adenosine.

A) Responder T cells obtained from IRBP-immunized B6 mice were co-cultured with BMDCs (T:DC ratio = 10:1) which were pre-exposed to TLR4 (LPS), TLR3 ligand (Poly IC) or TLR2 ligand (Pam3), as indicated.

B) Synergistic effect between adenosine analogue NECA and TLR3 ligand (Pam3) in augmenting BMDCs' $\gamma\delta$ -stimulating activity. BMDCs were treated with a Pam3 (right panels) or remained untreated (left panels), and with or without NECA (100 nM) treatment for 24 h., before co-cultured with responder CD3+ T cells. After 48 h, the responder T cells were stained with PE-anti- $\alpha\beta$ and FITC-anti- $\gamma\delta$ antibodies, followed by FACS analysis.